Innoviva (INVA) Assets Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.03% |
| Dec 31, 2025 | 10.34% |
| Sep 30, 2025 | 9.15% |
| Jun 30, 2025 | 8.68% |
| Mar 31, 2025 | 9.74% |
| Dec 31, 2024 | 12.41% |
| Sep 30, 2024 | 12.75% |
| Jun 30, 2024 | 13.78% |
| Mar 31, 2024 | 16.52% |
| Dec 31, 2023 | 17.80% |
| Sep 30, 2023 | 33.74% |
| Jun 30, 2023 | 26.98% |
| Mar 31, 2023 | 32.49% |
| Dec 31, 2022 | 27.37% |
| Sep 30, 2022 | 27.70% |
| Jun 30, 2022 | 25.05% |
| Mar 31, 2022 | 23.09% |
| Dec 31, 2021 | 19.57% |
| Sep 30, 2021 | 19.08% |
| Jun 30, 2021 | 15.85% |
| Mar 31, 2021 | 22.92% |
| Dec 31, 2020 | 19.57% |
| Sep 30, 2020 | 16.08% |
| Jun 30, 2020 | 13.74% |
| Mar 31, 2020 | 10.03% |
| Dec 31, 2019 | 6.80% |
| Sep 30, 2019 | 4.07% |
| Jun 30, 2019 | 1.18% |
| Mar 31, 2019 | -0.50% |
| Dec 31, 2018 | -4.25% |
| Sep 30, 2018 | -16.05% |
| Jun 30, 2018 | -10.65% |
| Mar 31, 2018 | -14.09% |
| Dec 31, 2017 | -0.07% |
| Sep 30, 2017 | 0.36% |
| Jun 30, 2017 | -1.41% |
| Mar 31, 2017 | 12.47% |
| Dec 31, 2016 | 7.93% |
| Sep 30, 2016 | 5.51% |
| Jun 30, 2016 | 4.52% |
| Dec 31, 2015 | 4.31% |